XBIO Average Annual Return Since 2014
Growth of $10,000.00
Without Dividends Reinvested Into XBIO

Also see:
XBIO stock yearly return 2016
XBIO stock yearly return 2017
XBIO stock yearly return 2018
XBIO stock yearly return 2019
XBIO stock yearly return 2020
XBIO stock yearly return 2021
XBIO YTD return
Compare XBIO average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Start date: 06/30/2016
End date: 09/23/2022
Start price/share: $61.20
End price/share: $0.59
Dividends collected/share: $0.00
Total return: -99.04%
XBIO Average Annual Return: -52.55%
Starting investment: $10,000.00
Ending investment: $95.75
Years: 6.24

XBIO average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Xenetic Biosciences is a biopharmaceutical company. Co.'s drug candidates pipeline include: XCART, which is a CAR T cell platform technology engineered to target patient-specific tumor neoantigens; ErepoXen (polysialylated erythropoietin), which uses Co.'s PolyXen platform technology for the treatment of anemia in chronic kidney disease patients; XBIO-101, which is an internal candidate with orphan drug designation from the U.S. Food and Drug Administration for the potential treatment of progesterone receptor negative endometrial cancer in conjunction with progesterone therapy; and OncoHist, which utilizes the properties of modified human histone H1.3 for targeted cell killing. The XBIO average annual return since 2016 is shown above.

The Average Annual Return on the XBIO average annual return since 2016 page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether XBIO average annual return since 2016 or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the XBIO average annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes

Email EnvelopeFree XBIO Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Xenetic Biosciences (XBIO) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

XCUR Average Annual Return
XERS Average Annual Return
XFOR Average Annual Return
XGN Average Annual Return
XNCR Average Annual Return
XOMA Average Annual Return
XRAY Average Annual Return
YMAB Average Annual Return
YMTX Average Annual Return
YTEN Average Annual Return
More Healthcare companies »


XBIO Average Annual Return Since 2014 | www.AverageAnnualReturn.com | Copyright © 2021 - 2022, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.